Risk of venous thromboembolism with upadacitinib in rheumatoid arthritis: a meta-analysis.
Upadacitinib not linked to higher venous thromboembolism risk in rheumatoid arthritis
Risk of venous thromboembolism with upadacitinib in rheumatoid arthritis: a meta-analysis.
Upadacitinib, a selective Janus kinase (janus kinase) inhibitor, has become an effective therapeutic option for rheumatoid arthritis (rheumatoid arthritis).
We systematically searched databases, including PubMed, Embase, and the Cochrane Library, for relevant randomized controlled trials (randomized controlled trials) in rheumatoid arthritis patients that reported venous thromboembolism and its subtypes.
clotting risk was no higher with upadacitinib than comparators
However, venous thromboembolism (venous thromboembolism) represents a potentially life-threatening complication associated with janus kinase inhibition, and uncertainties remain regarding the risk of specific venous thromboembolism subtypes with upadacitinib, including non-fatal pulmonary embolism (nPE), non-fatal deep vein thrombosis (nDVT), and concurrent pulmonary embolism and deep vein thrombosis (cPE-DVT).
Heterogeneity was absent across all analyses (I 2 = 0% for all outcomes).
In this meta-analysis of randomized controlled trials, upadacitinib did not demonstrate a significantly increased risk of venous thromboembolism or its subtypes compared to controls in the studied rheumatoid arthritis population.
Despite the low overall incidence and lack of signal in this cohort, the potential venous thromboembolism risk highlighted by the FDA boxed warning necessitates careful patient selection based on comorbidities and dosage.